Antibody-drug Conjugates Market Survey Report 2020 Along with Statistics, Forecasts till 2025

The Antibody-drug Conjugates Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2019-2025. The Antibody-drug Conjugates market report is a valuable source of data for business strategists. It provides the industry overview with market growth analysis with a historical & futuristic perspective for the following parameters; cost, revenue, demands and supply data (as applicable). Report explores the current outlook in global and key regions from the perspective of players, countries, product types and end industries. This Antibody-drug Conjugates Market study provides comprehensive data which enhances the understanding, scope and application of this report.

Top Companies in the Global Antibody-drug Conjugates Market
Seattle Genetics(NASDAQ:SGEN) (US), ImmunoGen, Inc.(NASDAQ:IMGN) (US), Roche Holding AG (OTCMKTS:RHHBY)(Switzerland), Genentech (US), Concortis Biotherapeutics (US), Agensys, Inc. (US), Antikor (UK), Immunomedics (US), Pfizer Inc. (US), Celldex Therapeutics (US), Millennium Pharmaceuticals (US), AbbVie Inc. (US), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (US), Mersana Therapeutics (US), Synthon (US), Heidelberg Pharma (Germany), Oxford BioTherapeutics (US), and others, among others.

According to this study, over the next five years the Antibody-drug Conjugates market will register a 3.1% CAGR in terms of revenue, the global market size will reach $ 2926.2 million by 2025, from $ 2588.6 million in 2019.

Market Overview-
Antibody drug conjugates comprise three parts, mainly a specific antibody for binding, a cytotoxic agent designed to kill target cancer cells, and a chemical linker for attaching the cytotoxic agent to the antibody. These drug conjugates are regarded to be the new age of therapeutic agents. The combine effect of targeting specific types of cells and the killing ability of cytotoxic drugs make this drug conjugate the ideal one for treatment of various cancers. The success of this technology has become possible only with increasing technological advancements. The potential of a cytotoxic drug embedded in the antibody drug conjugate is increased by 100-1000 fold more than the potential of cytotoxic drug when it acts alone.

Get Free Sample PDF Copy of Latest Research on Antibody-drug Conjugates Market 2020 Before the purchase
https://www.marketinsightsreports.com/reports/03181910006/global-antibody-drug-conjugates-market-growth-2020-2025/inquiry?Mode=46&Source=OpenPR

Market Insights-
North America ranks the top in terms of global market size of Antibody Drug Conjugate, it consists of 59.12% of the international market in 2016. Europe comes the second, with 27.70% of the global market. Asia Pacific consists of 6.54%of the Antibody Drug Conjugate market in the same year.

Takeda ranks the first in terms of revenue share in Global market of Antibody Drug Conjugate, occupies 54.17% of market share in 2016; While, Roche, with a market share of 35.11%, comes the second; The other companies consist of approximately 10.72% of the global market in 2016.

Trnding News

Seattle Genetics(NASDAQ:SGEN):
Seattle genetics and astellas get hold of FDA leap Breakthrough Therapy Designation for PADCEV (enfortumab vedotin-ejfv) in mixture with Pembrolizumab in First-Line Advanced Bladder Cancer:
Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PADCEV(TM) (enfortumab vedotin-ejfv) in combination with Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA (pembrolizumab) for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting.

(Source- finance.yahoo)

Roche Holding AG (OTCMKTS:RHHBY)(Switzerland)
FDA Accepts Genentech's New Drug Application for Xofluza for the Treatment of Influenza in Children:
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) as well as two supplemental New Drug Applications (sNDA) for Xofluza (baloxavir marboxil). The FDA accepted a NDA for a new formulation of Xofluza as one-dose granules for oral suspension (2 mg/mL), potentially offering a more convenient option for children and those who have difficulty swallowing. In addition, the application seeks approval of Xofluza for the treatment of acute uncomplicated influenza in otherwise healthy children aged one to less than 12 years of age who have been symptomatic for no more than 48 hours. The FDA also accepted an sNDA for post-exposure prophylaxis of influenza in people one year of age and older for both the oral suspension and currently-available tablet formulation. The FDA is expected to make a decision on these approvals by November 23, 2020.

(Source- finance.yahoo)

ImmunoGen, Inc.(NASDAQ:IMGN) (US)
ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway (Revised):
ImmunoGen, Inc.IMGN announced that the FDA has advised to conduct a new single-arm pivotal study, which can support accelerated approval for its lead candidate, mirvetuximab soravtansine, in ovarian cancer. We note that the FDA had recommended a new monotherapy study on the candidate in May, following the failure of phase III study - FORWARD 1.
Based on the FDA's guidance, the company is planning to initiate a pivotal study, SORAYA, in patients with platinum-resistant ovarian cancer whose tumors express high levels of FR alpha and who have received prior treatment with Roche's RHHBY Avastin (bevacizumab). The company is expected to start enrolling patients in the SORAYA study by the next quarter, with top-line data expected to be available by mid-2021. The company is anticipating to file a regulatory application in the second half of 2021, seeking accelerated approval for mirvetuximab soravtansine, if the study is completed successfully.

(Source- finance.yahoo)

The Antibody-drug Conjugates market can be divided based on product types and its sub-type, major applications and Third Party usage area, and important regions.

This report segments the global Antibody-drug Conjugates Market on the basis of Types are
Adcetris
Kadcyla

On The basis Of Application, the Global Antibody-drug Conjugates Market is Segmented into
Breast Cancer
Lymphoma

(Exclusive Offer: Flat 30% discount on this report)
Inquire for Discount
https://www.marketinsightsreports.com/reports/03181910006/global-antibody-drug-conjugates-market-growth-2020-2025/dscount?Mode=46&Source=OpenPR

Regions Are covered By Antibody-drug Conjugates Market Report 2020 To 2025.

North America, Europe, China, Japan, Southeast Asia, India.
North America (USA, Canada and Mexico).
Europe (Germany, France, UK, Russia and Italy).
Asia-Pacific (China, Japan, Korea, India and Southeast Asia).

Significant Features that are under Offering and Key Highlights of the Reports

-Detailed overview of Antibody-drug Conjugates Market
-Changing Antibody-drug Conjugates market dynamics of the industry
-In-depth market segmentation by Type, Application etc.
-Historical, current and projected Antibody-drug Conjugates market size in terms of volume and value
Recent industry trends and developments
-Competitive landscape of Antibody-drug Conjugates Market
-Strategies of key players and product offerings
-Potential and niche segments/regions exhibiting promising growth.

Frequently Asked Questions about Antibody-drug Conjugates market:

- What are the recent developments and government policies?
- Why might we forecast a downturn in a particular economy next year?
- Why do we say a currency is set to appreciate?
- What countries and sectors offer the highest potential?
- Where are the greatest dangers?

The report has 150 tables and figures browse the report description and TOC
https://www.marketinsightsreports.com/reports/03181910006/global-antibody-drug-conjugates-market-growth-2020-2025?Mode=46&Source=OpenPR

We Also Offer Customization on report based on specific client Requirement
Free country Level analysis for any 5 countries of your choice.
Free Competitive analysis of any 5 key market players.
Free 40 analyst hours to cover any other data point.

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Address:

Market Insights Reports
4893, Pepper drive, Harrisburg ,NC 28075,United States

+Contact US :

Irfan Tamboli (Head of Sales)
Market Insights Reports
Phone: + 1704 266 3234 | Mob: +91-750-707-8687
sales@marketinsightsreports.com
irfan@marketinsightsreports.com

ABOUT US
Market Insights Reports is an online market research reports library of 500,000 in-depth studies of over 5000 micro markets. Market Insights Reports offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

This release was published on openPR.